524661 — Welcure Drugs and Pharmaceuticals Income Statement
0.000.00%
- IN₹988.75m
- IN₹986.59m
- 36
- 49
- 88
- 63
Annual income statement for Welcure Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | Interim Report | ARS |
Standards: | IAS | IAS | IAS | — | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.825 | 1.33 | 1.05 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0 | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.923 | 0.784 | 0.814 | 1.22 | 2.69 |
Operating Profit | -0.098 | 0.549 | 0.236 | -1.22 | -2.69 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.094 | 0.551 | 0.236 | -0.526 | -1.75 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.094 | 0.551 | 0.236 | -0.526 | -1.75 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.094 | 0.551 | 0.236 | -0.526 | -1.75 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.094 | 0.551 | 0.236 | -0.526 | -1.75 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.008 | 0.045 | 0.019 | -0.004 | -0.129 |